𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Five oximes (K-27, K-33, K-48, BI-6 and methoxime) in comparison with pralidoxime: survival in rats exposed to the organophosphate paraoxon

✍ Scribed by G. A. Petroianu; S. M. Nurulain; N. Nagelkerke; M. A. H. Al-Sultan; K. Kuča; J. Kassa


Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
266 KB
Volume
26
Category
Article
ISSN
0260-437X

No coin nor oath required. For personal study only.

✦ Synopsis


Oximes are cholinesterase reactivators used in organophosphorus poisoning. Clinical experience with pralidoxime (PRX) and other oximes is disappointing and their routine use has been questioned. In addition it is known that not all oximes are equally effective against all existing organophosphorus compounds. There is a demand for broadspectrum reactivators with a higher efficacy than PRX. Based on our previous in vitro work the protection conferred by the various new oximes against inhibition by paraoxon as quantified by the IC 50 shift (nM increase in the IC 50 of the inhibitor per µ µ µ µ µM oxime present) is: 0.3 (PRX), 0.4 (methoxime; MMC-4), 1 (K-33), 1.2 (BI-6), 1.5 (K-48) and 3.7 (K-27). The purpose of the study was to quantify in vivo the extent of oxime-conferred protection, using paraoxon (POX) as a cholinesterase inhibitor and to test whether in vitro efficacy translates to protection from mortality.

There were seven groups of six rats in each cycle of the experiment. Group 1 (G1) received 1 µ µ µ µ µmol POX (≈ ≈ ≈ ≈ ≈ LD 75 ), the other groups (G2-G7) received 1 µ µ µ µ µmol POX + + + + + of one the six reactivators. The animals were monitored for 48 h and the time of mortality was recorded. The procedure was repeated five times (cycles). All substances were applied i.p. The experiments were repeated using 2, 3, 5 and 10 µ µ µ µ µmol POX. Mortality data were compared and hazards ratios (relative risks) ranked using the Cox proportional hazards model using POX dose and group (reactivator) as time-independent covariables. The relative risk of death estimated by Cox analysis (95% CI) in oxime treated animals when compared with untreated animals, adjusted for POX dose (high/low) was K


📜 SIMILAR VOLUMES


Five oximes (K-27, K-48, obidoxime, HI-6
✍ G. A. Petroianu; S. M. Nurulain; N. Nagelkerke; M Shafiullah; J. Kassa; K. Kuča 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB

## Abstract There is a clear need for broad‐spectrum cholinesterase reactivators (active against a multitude of organophosphorus ester enzyme inhibitors) with a higher efficacy than pralidoxime. The purpose of the study was to quantify __in vivo__ the extent of oxime‐conferred protection, using met

Five oximes (K-27, K-33, K-48, BI-6 and
✍ G. A. Petroianu; K. Arafat; K. Kuča; J. Kassa 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 599 KB

Oximes are cholinesterase reactivators of use in poisoning with organophosphorus compounds. Pralidoxime (PRX) is used clinically as an adjunct to atropine in such exposure. Clinical experience with PRX (and other oximes) is, however, disappointing and routine use has been questioned. In addition it